Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Employees32,500IPOOct 28, 1998SIC2834HQRoute 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
to
Financials (EUR)
Profitability
Metric
Current
Margins
Gross Margin
71.1%
Operating Margin
28.5%
EBITDA Margin
31.6%
Net Margin
14.6%
OCF Margin
29.1%
FCF Margin
26.4%
Returns on Capital
ROE
40.0%
ROA
7.6%
ROIC
13.0%
ROCE
16.5%
ROC (Greenblatt)
128.9%
3Y ROIIC
−35.3%
Consistency
Years Profitable / 10Y
8
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
18.07
Forward P/E
9.90
P/E ex-NRI
10.13
Shiller P/E (CAPE)
38.97
Cash Flow Multiples
P/FCF
9.89
P/OCF
8.98
P/Owner Earnings
14.74
FCF Yield
10.12%
Enterprise Value Multiples
EV / EBIT
14.57
EV / Forward EBIT
10.89
EV / EBITDA
10.73
EV / Forward EBITDA
9.49
EV / Revenue
3.39
EV / Forward Revenue
3.48
Asset / Sales
P/S
2.64
P/B
6.87
P/Tangible Book
—
Growth-Adjusted
PEG
3.62
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
4.05%
Forward Dividend Yield
4.01%
3Y Dividend Growth
4.4%
Payout Ratio
0.40
5Y Yield on Cost
5.50%
Buybacks & Dilution
3Y Buyback Ratio
0.60%
5Y Share Change
−9.7%
Combined
Shareholder Yield
6.68%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
2.55
Gross Debt / EBITDA
3.10
Cash / Debt
0.23
Equity / Assets
0.21
Coverage
Interest Coverage
7.26
Short-Term Liquidity
Current Ratio
1.26
Quick Ratio
1.14
Cash Ratio
0.46
Composite Scores
Piotroski F-Score
8
Altman Z-Score
2.35
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-04-02
$0.63
2026-05-01
2026-01-02
$0.63
2026-02-02
2025-10-03
$0.62
2025-11-03
2025-07-03
$0.62
2025-08-01
2025-04-04
$0.62
2025-05-01
2025-01-03
$0.62
2025-02-03
2024-10-04
$0.6
2024-11-01
2024-07-05
$0.6
2024-08-01
2024-04-04
$0.6
2024-05-01
2024-01-04
$0.6
2024-02-01
10 of 146
View allDate
Transcript
Type
2026-07-30
Q2 2026 Bristol-Myers Squibb Co Earnings Call Transcript
Earnings Call
2026-06-09
Bristol-Myers Squibb Co at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-14
Bristol-Myers Squibb Co at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-04-30
Q1 2026 Bristol-Myers Squibb Co Earnings Call Transcript
Earnings Call
2026-03-02
Bristol-Myers Squibb Co at TD Cowen Healthcare Conference Transcript
Conference Presentations
2026-02-05
Q4 2025 Bristol-Myers Squibb Co Earnings Call Transcript
Earnings Call
2026-01-12
Bristol-Myers Squibb Co at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-11
Bristol-Myers Squibb Co Virtual Investor Presentation on Hematology Programs Transcript
Analyst/Investor Call
2025-12-04
Bristol-Myers Squibb Co at Citi Global Healthcare Conference Transcript
Conference Presentations
2025-10-30
Q3 2025 Bristol-Myers Squibb Co Earnings Call Transcript
Earnings Call
10 of 108
5-Step DuPont Analysis
ROE %
39.59%
×
×
Net Margin %
14.76%
×
×
Operating Margin %
28.53%
Operating Income
€12.01B
÷
Revenue
€42.09B
×
Tax Burden
0.7580
Net Income
€6.21B
÷
Pretax Income
€8.19B
×
Interest Burden
0.6823
Pretax Income
€8.19B
÷
Operating Income
€12.01B
×
Asset Turnover
0.51
÷
Revenue
€42.09B
÷
Average Total Assets
€82.66B
Begin Total Assets
€88.44B
End Total Assets
€76.89B
×
Equity Multiplier
5.27
÷
Avg Total Assets
€82.66B
÷
Avg Stockholders Equity
€15.69B
Begin Equity
€15.60B
End Equity
€15.78B